Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04921345 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT04921345 is a Phase 2 study of Moderate-to-Severe Atopic Dermatitis that has completed, run by Galderma R&D. The registered enrollment target is 105 participants, below the 642-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT04921345, a Phase 2 study of Moderate-to-Severe Atopic Dermatitis, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Nemolizumab
Study Locations (20)
Other
- Galderma Investigational Site #6218 - Hellerup
- Galderma Investigational Site #6147 - Budapest
- Galderma Investigational Site #5531 - Szeged
- Galderma Investigational Site #5570 - Lodz
- Galderma Investigational Site #6237 - Ostrowiec Świętokrzyski
- Galderma Investigational Site #5495 - Rzeszów
California
- Galderma Investigational Site #8636 - Fountain Valley
- Galderma Investigational Site #9937 - San Diego
- Galderma Investigational Site #9930 - Vista
Michigan
- Galderma Investigational Site #8155 - Troy
- Galderma Investigational Site #8560 - West Bloomfield
New York
- Galderma Investigational Site #8242 - Brooklyn
- Galderma Investigational Site #9938 - New York
Texas
- Galderma Investigational Site #9931 - Beaumont
- Galderma Investigational Site #78218-3128 - San Antonio
Florida
- Galderma Investigational Site #9929 - Coral Gables
Indiana
- Galderma Investigational Site #8142 - Indianapolis
Kentucky
- Galderma Investigational Site #8092 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04921345
The ClinicalTrials.gov registry entry for NCT04921345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (84% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate-to-Severe Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Nemolizumab is the first listed.
NCT04921345 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT04921345 about?
NCT04921345 is a clinical study titled "Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT04921345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2021-06-24. Estimated completion is 2025-04-28.
What conditions does trial NCT04921345 study?
This clinical trial studies the following conditions: Moderate-to-Severe Atopic Dermatitis.
What interventions are being tested in trial NCT04921345?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT04921345?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04921345 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-Severe Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
COMPLETED · Phase 3
-
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.